• Australian (ASX) Stock Market Forum

Hello and welcome to Aussie Stock Forums!

To gain full access you must register. Registration is free and takes only a few seconds to complete.

Already a member? Log in here.

PKS - PKS Holdings

Discussion in 'Stocks I-P' started by System, May 13, 2019.

  1. System

    System Administrator

    Posts:
    2,913
    Likes Received:
    49
    Joined:
    Jun 27, 2010
    PKS is an Australian healthcare technology company that provides a proprietary subscription based Clinical Decision Support system (CDS) called "RippleDown". RippleDown automates the human decision-making process within healthcare organisations based on rules set within the organisation by domain experts.

    PKS' customers include laboratories, hospitals and other healthcare organisations and RippleDown was developed to address major issues within these organisations, including:
    • the increased financial pressures that are being faced;
    • a continual rise in patient volumes;
    • rising expectations for patient outcomes; and
    • succession risk from changes in personnel.
    The RippleDown CDS software consists of two separate products:
    • RippleDown Expert that has applications for the clinical side of a healthcare organisation's operations; and
    • RippleDown Auditor that has applications for the financial side of a healthcare organisation's operations.
    PKS distributes its products via two key channels, being direct sales using its own sales resources and through three global channel partners, being Abbott, Philips and Thermo Fisher. Sales through channel partners represented approximately 30% of total revenue in FY2018, which has grown from 10% of total revenue in FY2016.

    It is anticipated that PKS will list on the ASX during June 2019.

    https://pks.com.au
     
  2. Dona Ferentes

    Dona Ferentes

    Posts:
    1,193
    Likes Received:
    1,220
    Joined:
    Jan 11, 2016
    IPO at 20c, got above that for a while but in the dumps since then and only around 15-16c

    Direct sales or a Channel Partner,the company doesn't seem to be picking up many licenses. Maybe aiming for pathology first and moving into the larger (usually colocated) hospital businesses will work but, so far, very disappointing. Like most of these efforts (ALC another).
     
    Trav. likes this.
  3. Trav.

    Trav.

    Posts:
    690
    Likes Received:
    794
    Joined:
    Nov 27, 2017
    Just some musings on the chart below as my latest phase in charting has caught some patterns here that seem to have played out well.

    Will it recover and BO for a trade ( not for me as I have been burnt to many times at this end of the cesspool ) ??

    upload_2020-1-27_18-0-54.png
     
    Dona Ferentes and sptrawler like this.
  4. Trav.

    Trav.

    Posts:
    690
    Likes Received:
    794
    Joined:
    Nov 27, 2017
    Just updating the thread and SP has been bouncing between 14.5 and 15.5 cents over the last few days, which isn't a bad sign.

    The down trend appears to have slowed or completed and now the pause before the recover ??? interesting to watch
     
    sptrawler likes this.
  5. Dona Ferentes

    Dona Ferentes

    Posts:
    1,193
    Likes Received:
    1,220
    Joined:
    Jan 11, 2016
    Trading Halt - Capital raising for material acquisition
     
  6. Dona Ferentes

    Dona Ferentes

    Posts:
    1,193
    Likes Received:
    1,220
    Joined:
    Jan 11, 2016
    PKS has acquired 100% of Pavilion Health Australia Pty Ltd in an all scrip transaction.

    • Pavilion Health is an Australian cloud-based software company, operating under a Software as a Service (SaaS) model, providing audit and risk applications and consulting services to hospitals and governing health bodies globally.

    • The strategic benefits and synergies for this acquisition include:
    - Scale: the resulting combined entity increases revenue by c 113% (FY19A), diversifies customer base with a c 58% growth to 190+ customers;
    - Customers: strong cross and upselling product potential between complementary customer bases;
    - Technology: combined delivery of an enhanced product roadmap into hospitals and pathology sectors whilst facilitating trends of digitisation and use of analytics to improve efficacy and efficiency in healthcare; and
    - Management: bolster expertise of executive management with the addition of a COO, CTO and CCO from Pavilion.
    • Pavilion Health audited sales for FY2019 were $4.37 million and will double the sales for PKS. Operational EBITDA for FY2019 was $ 1.66 million.

    • The acquisition is on an all scrip, cash free and debt free basis with Pavilion Health shareholders being issued 65.2 million new PKS shares, which equates to 35% of the company post acquisition. The issue of these shares is subject to PKS shareholder approval at an Extraordinary General Meeting.
    • At the share price of $0.13 as of 17th April 2020, it values the acquisition at 1.9x FY19 revenue and 5.1x FY19 Operational EBITDA

    - punters like it (now 16c), as the new entity is almost double in size, and "is consistent with PKS’ growth strategies to acquire complimentary healthcare technology companies and expand beyond pathology."

     

Share This Page